Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers

Molecules

Fabrice Tranchida¹  Laetitia Shintu¹  Farhat Ben Ayed²  Sonia Mezrioui²  Oumaima Zidi³  Nessrine Souai³  Jean-Marc Sabatier⁴  Soumaya Kouidhi⁵  Ameur Cherif⁵  Amor Mosbah⁵  Amel Mezlini⁶  Henda Raies⁶ 

[1] Aix Marseille Univ, CNRS, Centrale Marseille, iSm2, 13284 Marseille, France;Association Tunisienne de Lutte Contre le Cancer (ATCC), Tunis 1938, Tunisia;Department of Biology, Faculty of Sciences of Tunis, Farhat Hachad Universitary Campus, University of Tunis El Manar, Rommana, Tunis 1068, Tunisia;Faculté de Pharmacie, Institute of NeuroPhysiopathology (INP), UMR 7051, 27, Boulevard Jean-Moulin, CEDEX, 13005 Marseille, France;Laboratory of Biotechnology and Valorisation of Bio-GeoRessources, Higher Institute of Biotechnology of Sidi Thabet, BiotechPole of Sidi Thabet, University of Manouba, Ariana 2020, Tunisia;Service d’Oncologie Médicale, Hôpital Salah-Azaïz, Tunis 1006, Tunisia;

关键词: breast cancer (BC);    metabolomics;    gut microbiota;    dysbiosis;    metabolites;    biomarkers;   

DOI  :  10.3390/molecules26082266

来源: DOAJ

【 摘 要 】

Breast cancer (BC) is the most common form of cancer among women worldwide. Despite the huge advancements in its treatment, the exact etiology of breast cancer still remains unresolved. There is an increasing interest in the role of the gut microbiome in modulating the anti-cancer therapeutic response. It seems that alteration of the microbiome-derived metabolome potentially promotes carcinogenesis. Taken together, metabolomics has arisen as a fascinating new omics field to screen promising metabolic biomarkers. In this study, fecal metabolite profiling was performed using NMR spectroscopy, to identify potential biomarker candidates that can predict response to neoadjuvant chemotherapy (NAC) for breast cancer. Metabolic profiles of feces from patients (n = 8) following chemotherapy treatment cycles were studied. Interestingly, amino acids were found to be upregulated, while lactate and fumaric acid were downregulated in patients under the second and third cycles compared with patients before treatment. Furthermore, short-chain fatty acids (SCFAs) were significantly differentiated between the studied groups. These results strongly suggest that chemotherapy treatment plays a key role in modulating the fecal metabolomic profile of BC patients. In conclusion, we demonstrate the feasibility of identifying specific fecal metabolic profiles reflecting biochemical changes that occur during the chemotherapy treatment. These data give an interesting insight that may complement and improve clinical tools for BC monitoring.

【 授权许可】

Unknown